Changes of mitochondrial mass in the hemopoietic stem cell line FDCP-mix after treatment with etoposide: a correlative study by multiparameter flow cytometry and confocal and electron microscopy.
FDCP-Mix, a pluripotent murine hemopoietic stem cell line which undergoes typical internucleosomal cleavage of DNA when induced to apoptosis by either drugs or withdrawal of growth factor (interleukin-3) was studied after treatment with the topoisomerase II inhibitor etoposide (0.5-4 microM). An increase in autolytic activity was the major early morphological change within the cytoplasm, with mitochondria as the main target for autolytic digestion. Despite this macroautophagy, thin sections showed a high number of mitochondria, suggesting mitochondrial proliferation as a result of drug treatment. This observation of an increase in the number of mitochondria was confirmed by flow cytometric studies of mitochondrial overall mass. Multiparameter flow cytometry of cells double stained with propidium iodide and nonyl-acridine orange gave an accurate assay for mitochondrial mass in relation to cell cycle stages. The increase in mitochondrial mass was found in all cell cycle stages. The results suggest a drug-induced proliferation of mitochondria separate from the processes involved in the doubling of mitochondrial mass during the cell cycle and a decline of mitochondria in the later stages of apoptosis.
D000165:Acridine Orange / Q000031:analogs & derivatives; D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D001329:Autolysis; D002460:Cell Line; D004396:Coloring Agents; D003593:Cytoplasm / Q000187:drug effects / Q000648:ultrastructure; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005047:Etoposide / Q000494:pharmacology*; D005434:Flow Cytometry / Q000379:methods; D016195:G2 Phase; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000648:ultrastructure; D007377:Interleukin-3 / Q000502:physiology; D051379:Mice; D018613:Microscopy, Confocal; D008854:Microscopy, Electron; D008928:Mitochondria / Q000187:drug effects*; D011419:Propidium; D059005:Topoisomerase II Inhibitors
D004396:Coloring Agents; D004791:Enzyme Inhibitors; D007377:Interleukin-3; D059005:Topoisomerase II Inhibitors; D011419:Propidium; C056258:N(10)-nonylacridine orange; D005047:Etoposide; D000165:Acridine Orange